ライフサイエンスコーパス: temsirolimus

1 ion, adverse events, and pharmacokinetics of temsirolimus.

2 emsirolimus and 160 mg of neratinib/50 mg of temsirolimus.

3 or-suppressive effects of the mTOR inhibitor temsirolimus.

4 e inhibition of tumor growth by Ku0063794 or temsirolimus.

5 ly sensitized SW1736 cells to perifosine and temsirolimus.

6 ine xenograft tumor models were treated with temsirolimus.

7 tinib, lapatinib, bortezomib, sorafenib, and temsirolimus.

8 Temsirolimus 15 mg plus IFN 6 MU is the recommended dose

9 The recommended dose was temsirolimus 15 mg/IFN 6 MU based on dose-limiting toxic

10 e daily oral ibrutinib 560 mg or intravenous temsirolimus (175 mg on days 1, 8, and 15 of cycle 1; 75

11 B (bevacizumab 10 mg/kg IV every 2 weeks and temsirolimus 25 mg IV every week), C (bevacizumab 5 mg/k

12 26), or D (sorafenib 200 mg twice daily and temsirolimus 25 mg IV weekly).

13 8 years) at 35 centres in the USA were given temsirolimus 25 mg/week, and rituximab 375 mg/m(2) per w

14 group, to receive the combination of either temsirolimus (25 mg intravenously, weekly) or IFN (9 MIU

15 with cixutumumab (6 mg/kg, intravenous) and temsirolimus (25 mg, intravenous flat dose) in 6-week cy

16 d or refractory MCL were eligible to receive temsirolimus 250 mg intravenously every week as a single

17 temsirolimus group also received intravenous temsirolimus (35 mg/m(2) per dose) on days 1 and 8, wher

18 Lipopolysaccharide (1.5 mg/kg), Temsirolimus (5 mg/kg), AICAR (100 mg/kg).

19 onto a multicenter, ascending-dose study of temsirolimus (5, 10, 15, 20, or 25 mg) administered intr

20 the ULN, OS was significantly improved with temsirolimus (6.9 v 4.2 months; P < .002).

21 n due to adverse events for ibrutinib versus temsirolimus (9 [6%] vs 36 [26%]).

22 4 months), and 7.4 months for sorafenib plus temsirolimus (90% CI, 5.6 to 7.9 months).

23 0.8 months), 7.6 months for bevacizumab plus temsirolimus (90% CI, 6.7 to 9.2 months), 9.2 months for

24 Temsirolimus, a sirolimus analog, eliminated the effect

25 Temsirolimus, a specific inhibitor of the mammalian targ

26 Patients who received temsirolimus alone had longer overall survival (hazard r

27 he response and safety of the combination of temsirolimus (an mTOR inhibitor) and bortezomib in patie

28 Temsirolimus, an inhibitor of the mammalian target of ra

29 sible pan-HER tyrosine kinase inhibitor, and temsirolimus, an mTOR inhibitor, in patients with advanc

30 ere identified: 200 mg of neratinib/25 mg of temsirolimus and 160 mg of neratinib/50 mg of temsirolim

31 randomly assigned to irinotecan-temozolomide-temsirolimus and 17 to irinotecan-temozolomide-dinutuxim

32 aximum blood concentration was 292 ng/mL for temsirolimus and 37.2 ng/mL for its metabolite sirolimus

33 The combination of temsirolimus and bevacizumab had substantial activity an

34 Rapamycin analogs, temsirolimus and everolimus, are approved for the treatm

35 The combination of temsirolimus and IFN has an acceptable safety profile an

36 ting, which were observed at higher doses of temsirolimus and IFN.

37 se and safety profile for the combination of temsirolimus and interferon alfa (IFN) were determined i

38 The sum of temsirolimus and sirolimus areas under the concentration

39 tive mammalian target of rapamycin inhibitor temsirolimus and the protein synthesis inhibitor anisomy

40 me inhibitors (bortezomib), mTOR inhibitors (temsirolimus), and immunomodulatory drugs (lenalidomide)

41 The activity of sorafenib, temsirolimus, and bevacizumab administered in doublet co

42 ity of single-agent bortezomib, single-agent temsirolimus, and the combination of thalidomide and rit

43 Rapamycin analogs Everolimus and Temsirolimus are non-ATP-competitive mTORC1 inhibitors,

44 s knowledge we identified 2-deoxyglucose and temsirolimus as agents that can be added to a parthenoli

45 LDH, OS was not significantly improved with temsirolimus as compared with interferon therapy (11.7 v

46 Single-agent temsirolimus at a weekly dose of 75 mg was found to be a

47 Median PFS in patients treated with temsirolimus/bevacizumab (n = 400) versus IFN/bevacizuma

48 Temsirolimus/bevacizumab combination therapy was not sup

49 Patients receiving temsirolimus/bevacizumab reported significantly higher o

50 bjective response rate (27.0% nu 27.4%) with temsirolimus/bevacizumab versus IFN/bevacizumab, respect

51 Incidence of pneumonitis with temsirolimus/bevacizumab was 4.8%, mostly grade 1 or 2.

52 3 adverse events more common (P < .001) with temsirolimus/bevacizumab were mucosal inflammation, stom

53 GF1R/IR inhibitor with the rapalog inhibitor temsirolimus broadened the sensitivity of PDAC cells to

54 Consistent with this possibility, temsirolimus, but not Ku0063794, decreased tumor angioge

55 nhibition by the rapamycin derivatives (RDs) temsirolimus (CCI-779) and everolimus (RAD001) in acute

56 ent with the FDA-approved rapamycin analogue temsirolimus (CCI-779) blocks ANDV protein expression an

57 Temsirolimus (CCI-779) is a small-molecule inhibitor of

58 In this study, two doses of temsirolimus (CCI-779), a novel inhibitor of the mammali

59 OR pathway, in particular the mTOR inhibitor temsirolimus (CCI-779), induce autophagy, which can prom

60 Compared with the rapalog temsirolimus/CCI-779, WYE-132 elicited a substantially s

61 Temsirolimus CSF concentration was 2 ng/mL in one patien

62 with liposomal doxorubicin, bevacizumab, and temsirolimus (DAT) (N = 39) or liposomal doxorubicin, be

63 urther study whereas irinotecan-temozolomide-temsirolimus did not.

64 The administration of the mTOR inhibitor temsirolimus, even after established endotoxemia, induce

65 Those on letrozole/temsirolimus experienced more grade 3 to 4 events (37% v

66 Patients in the temsirolimus group also received intravenous temsirolimu

67 t was overall survival in comparisons of the temsirolimus group and the combination-therapy group wit

68 patients with serious adverse events in the temsirolimus group than in the interferon group (P=0.02)

69 ommon grade 3 or worse adverse events in the temsirolimus group were neutropenia (eight [44%] of 18 p

70 survival times in the interferon group, the temsirolimus group, and the combination-therapy group we

71 , and hyperlipidemia were more common in the temsirolimus group, whereas asthenia was more common in

72 A potential explanation is that temsirolimus has additional effects on the tumor microen

73 Single-agent temsirolimus has significant activity in both diffuse la

74 Single-agent temsirolimus has substantial antitumor activity in relap

75 Both ibrutinib and temsirolimus have shown single-agent activity in patient

76 ) for patients treated with ibrutinib versus temsirolimus (hazard ratio 0.43 [95% CI 0.32-0.58]; medi

77 As compared with interferon alfa, temsirolimus improved overall survival among patients wi

78 a rapamycin ester (cell cycle inhibitor-779, temsirolimus) improves motor performance in a transgenic

79 Ku0063794 was more effective than temsirolimus in decreasing the viability and growth of R

80 the first report of substantial activity of temsirolimus in lymphomas other than mantle cell lymphom

81 lysis showed improved PFS favoring letrozole/temsirolimus in patients </= age 65 years (9.0 v 5.6 mon

82 antibody cixutumumab and the mTOR inhibitor temsirolimus in patients with chemotherapy-refractory bo

83 free survival and better tolerability versus temsirolimus in patients with relapsed or refractory man

84 Ku0063794 was compared to temsirolimus in preclinical models for renal cell carcin

85 the efficacy and safety of ibrutinib versus temsirolimus in relapsed or refractory mantle-cell lymph

86 Bortezomib (in the United States) and temsirolimus (in Europe) are currently the only two trea

87 Temsirolimus inhibited the phosphorylation of p70S6K, a

88 Temsirolimus inhibits mammalian target of rapamycin and

89 The first cohort (n = 6) received 25 mg temsirolimus intravenously once per week.

90 Temsirolimus is a mammalian target of rapamycin (mTOR) i

91 Temsirolimus is designed for long-term use in patients a

92 Weekly intravenous temsirolimus is well tolerated in children with recurren

93 Temsirolimus is well tolerated in recurrent GBM patients

94 arget of rapamycin (mTOR) inhibitor CCI-779 (temsirolimus) is a recently Food and Drug Administration

95 Despite the effect of EIACs on temsirolimus metabolism, therapeutic levels were achieve

96 ents were randomised to ibrutinib (n=139) or temsirolimus (n=141).

97 mmalian target of rapamycin (mTOR) inhibitor temsirolimus occurred in virtually all the cells harbori

98 s 1, 8, 15, and 22 in combination with 25 mg temsirolimus on days 1, 8, 15, 22, and 29, for a cycle o

99 patients assigned to irinotecan-temozolomide-temsirolimus, one patient (6%; 95% CI 0.0-16.1) achieved

100 We aimed to test the addition of temsirolimus or dinutuximab to irinotecan-temozolomide i

101 ) to irinotecan and temozolomide plus either temsirolimus or dinutuximab, stratified by disease categ

102 ubicin, bevacizumab, and the mTOR inhibitors temsirolimus or everolimus using 21-day cycles.

103 on of mTORC2 signaling during treatment with temsirolimus or everolimus.

104 sunitinib, bevacizumab plus interferon-alfa, temsirolimus, or cytokines.

105 Temsirolimus peak concentration (Cmax), and sirolimus Cm

106 Consequently, the combination of temsirolimus plus CCR4 antagonist, a receptor highly exp

107 This study tested whether temsirolimus (previously known as CCI-779), an inhibitor

108 Temsirolimus produced an objective response rate of 9.2%

109 Temsirolimus reduces the number of aggregates seen in th

110 The most common temsirolimus-related adverse events of all grades were m

111 irolimus showed antitumor activity and 75 mg temsirolimus showed a generally tolerable safety profile

112 d or metastatic breast cancer, 75 and 250 mg temsirolimus showed antitumor activity and 75 mg temsiro

113 The combination of cixutumumab and temsirolimus shows clinical activity in patients with sa

114 mary hypothesis that ibrutinib compared with temsirolimus significantly improves progression-free sur

115 ials of the novel targeted agents sunitinib, temsirolimus, sorafenib, and bevacizumab.

116 mall-molecule targeted inhibitors sunitinib, temsirolimus, sorafenib, and the monoclonal antibody bev

117 We confirmed that temsirolimus targeted host mTOR complex 1 (mTORC1) and n

118 trate that the parthenolide, 2-deoxyglucose, temsirolimus (termed PDT) regimen is a potent means of t

119 lower in Caki-1 and 786-O cells treated with temsirolimus than cells treated with Ku0063794.

120 The rapalogs everolimus and temsirolimus that inhibit mTOR signaling are used as ant

121 The addition of temsirolimus to interferon did not improve survival.

122 Adding temsirolimus to letrozole did not improve PFS as first-l

123 iographic improvement was observed in 36% of temsirolimus-treated patients, and was associated with s

124 is effect was specific to viral proteins, as temsirolimus treatment did not block host protein synthe

125 ein expression, which were blocked following temsirolimus treatment.

126 ataxin-3 mice that were normalized following temsirolimus treatment.

127 perior activity was found with sunitinib and temsirolimus versus cytokines in first-line therapy.

128 Temsirolimus was administered in a 250-mg intravenous do

129 Intravenous temsirolimus was given at 15 or 25 mg and intravenous bo

130 In this phase II study (NCT00942747), temsirolimus was tested in patients with relapsed or ref

131 The combination of neratinib and temsirolimus was tolerable and demonstrated antitumor ac

132 randomly assigned to receive 75 or 250 mg of temsirolimus weekly as a 30-minute intravenous infusion.

133 weekly, or combination therapy with 15 mg of temsirolimus weekly plus 6 million U of interferon alfa

134 ll carcinoma to receive 25 mg of intravenous temsirolimus weekly, 3 million U of interferon alfa (wit

135 mmalian target of rapamycin (mTOR) inhibitor temsirolimus with letrozole in AI-naive patients.

136 Ibrutinib was better tolerated than temsirolimus, with grade 3 or higher treatment-emergent